These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
461 related articles for article (PubMed ID: 25678219)
1. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Mastellos DC; Yancopoulou D; Kokkinos P; Huber-Lang M; Hajishengallis G; Biglarnia AR; Lupu F; Nilsson B; Risitano AM; Ricklin D; Lambris JD Eur J Clin Invest; 2015 Apr; 45(4):423-40. PubMed ID: 25678219 [TBL] [Abstract][Full Text] [Related]
2. Evolution of compstatin family as therapeutic complement inhibitors. Huang Y Expert Opin Drug Discov; 2018 May; 13(5):435-444. PubMed ID: 29402126 [TBL] [Abstract][Full Text] [Related]
3. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Mastellos DC; Reis ES; Yancopoulou D; Hajishengallis G; Ricklin D; Lambris JD Immunobiology; 2016 Oct; 221(10):1046-57. PubMed ID: 27353192 [TBL] [Abstract][Full Text] [Related]
5. C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles. Furlong ST; Dutta AS; Coath MM; Gormley JJ; Hubbs SJ; Lloyd D; Mauger RC; Strimpler AM; Sylvester MA; Scott CW; Edwards PD Immunopharmacology; 2000 Jul; 48(2):199-212. PubMed ID: 10936517 [TBL] [Abstract][Full Text] [Related]
6. Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors. Lamers C; Xue X; Smieško M; van Son H; Wagner B; Berger N; Sfyroera G; Gros P; Lambris JD; Ricklin D Nat Commun; 2022 Sep; 13(1):5519. PubMed ID: 36127336 [TBL] [Abstract][Full Text] [Related]
7. New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile. Berger N; Alayi TD; Resuello RRG; Tuplano JV; Reis ES; Lambris JD J Med Chem; 2018 Jul; 61(14):6153-6162. PubMed ID: 29920096 [TBL] [Abstract][Full Text] [Related]
8. Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3. Soulika AM; Holland MC; Sfyroera G; Sahu A; Lambris JD Mol Immunol; 2006 May; 43(12):2023-9. PubMed ID: 16472861 [TBL] [Abstract][Full Text] [Related]
9. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Zhang Y; Shao D; Ricklin D; Hilkin BM; Nester CM; Lambris JD; Smith RJ Immunobiology; 2015 Aug; 220(8):993-8. PubMed ID: 25982307 [TBL] [Abstract][Full Text] [Related]
11. Improvement of the anti-C3 activity of compstatin using rational and combinatorial approaches. Morikis D; Soulika AM; Mallik B; Klepeis JL; Floudas CA; Lambris JD Biochem Soc Trans; 2004 Feb; 32(Pt 1):28-32. PubMed ID: 14748706 [TBL] [Abstract][Full Text] [Related]
12. Compstatin: a complement inhibitor on its way to clinical application. Ricklin D; Lambris JD Adv Exp Med Biol; 2008; 632():273-92. PubMed ID: 19025129 [TBL] [Abstract][Full Text] [Related]
13. Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates. Hughes S; Gumas J; Lee R; Rumano M; Berger N; Gautam AK; Sfyroera G; Chan AL; Gnanaguru G; Connor KM; Kim BJ; Dunaief JL; Ricklin D; Hajishengallis G; Yancopoulou D; Reis ES; Mastellos DC; Lambris JD Clin Immunol; 2020 May; 214():108391. PubMed ID: 32229292 [TBL] [Abstract][Full Text] [Related]
14. Molecular dynamics in drug design: new generations of compstatin analogs. Tamamis P; López de Victoria A; Gorham RD; Bellows-Peterson ML; Pierou P; Floudas CA; Morikis D; Archontis G Chem Biol Drug Des; 2012 May; 79(5):703-18. PubMed ID: 22233517 [TBL] [Abstract][Full Text] [Related]
15. A new generation of potent complement inhibitors of the Compstatin family. López de Victoria A; Gorham RD; Bellows-Peterson ML; Ling J; Lo DD; Floudas CA; Morikis D Chem Biol Drug Des; 2011 Jun; 77(6):431-40. PubMed ID: 21352502 [TBL] [Abstract][Full Text] [Related]
16. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Nilsson B; Larsson R; Hong J; Elgue G; Ekdahl KN; Sahu A; Lambris JD Blood; 1998 Sep; 92(5):1661-7. PubMed ID: 9716594 [TBL] [Abstract][Full Text] [Related]
17. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Risitano AM; Ricklin D; Huang Y; Reis ES; Chen H; Ricci P; Lin Z; Pascariello C; Raia M; Sica M; Del Vecchio L; Pane F; Lupu F; Notaro R; Resuello RR; DeAngelis RA; Lambris JD Blood; 2014 Mar; 123(13):2094-101. PubMed ID: 24497537 [TBL] [Abstract][Full Text] [Related]
18. Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40. Wang J; Wang L; Xiang Y; Ricklin D; Lambris JD; Chen G Clin Immunol; 2016 Jan; 162():37-44. PubMed ID: 26548839 [TBL] [Abstract][Full Text] [Related]
20. Thermodynamic studies on the interaction of the third complement component and its inhibitor, compstatin. Katragadda M; Morikis D; Lambris JD J Biol Chem; 2004 Dec; 279(53):54987-95. PubMed ID: 15489226 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]